{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T21:37:08Z","timestamp":1793223428331,"version":"4.5.0"},"reference-count":36,"publisher":"American Physiological Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American Journal of Physiology-Renal Physiology"],"published-print":{"date-parts":[[2008,8]]},"abstract":"<jats:p> Nonsteroidal anti-inflammatory cyclooxygenase inhibitors that function to reduce prostaglandin E<jats:sub>2<\/jats:sub> (PGE<jats:sub>2<\/jats:sub>) production have been widely reported as effective agents in models of urinary bladder overactivity. We therefore investigated a potential role for the PGE<jats:sub>2<\/jats:sub> receptor, EP3, in urinary bladder function by performing conscious, freely moving cystometry on EP3 receptor knockout (KO) mice. EP3 KO mice demonstrated an enhanced bladder capacity compared with wild-type (WT) mice (\u223c185% of WT) under control conditions, based on larger voided and infused bladder volumes. Infusion of the EP3 receptor agonist GR63799X into the bladder of WT mice reduced the bladder capacity. This was ineffective in EP3 KO mice that demonstrated a time-dependent increase in bladder capacity with GR63799X, an effect similar to that observed with vehicle in both genotypes. In addition, infusion of PGE<jats:sub>2<\/jats:sub> into WT mice induced bladder overactivity, an effect that was significantly blunted in the EP3 KO mice. The data reported here provide the first evidence supporting a functional role for EP3 receptors in normal urinary bladder function and implicate EP3 as a contributor to bladder overactivity during pathological conditions of enhanced PGE<jats:sub>2<\/jats:sub> production, as reported previously in overactive bladder patients. <\/jats:p>","DOI":"10.1152\/ajprenal.00054.2008","type":"journal-article","created":{"date-parts":[[2008,5,29]],"date-time":"2008-05-29T00:44:26Z","timestamp":1212021866000},"page":"F507-F514","source":"Crossref","is-referenced-by-count":52,"title":["Enhanced bladder capacity and reduced prostaglandin E<sub>2<\/sub>-mediated bladder hyperactivity in EP3 receptor knockout mice"],"prefix":"10.1152","volume":"295","author":[{"given":"Gerald P.","family":"McCafferty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake A.","family":"Misajet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Laping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard M.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin S.","family":"Thorneloe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"24","reference":[{"key":"R1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2006.06003.x"},{"key":"R2","unstructured":"Araki T, Yokoyama T, Kumon H. Effectiveness of a nonsteroidal anti-inflammatory drugs for nocturia in patients with benign prostatic hyperplasia: a prospective nonrandomized study of Loxoprofen sodium 60 mg once daily before sleeping. Acta Med Okayama 58: 45\u201349, 2004."},{"key":"R3","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2006.09.001"},{"key":"R4","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)55955-8"},{"key":"R5","doi-asserted-by":"publisher","DOI":"10.1038\/35039519"},{"key":"R6","unstructured":"Dionne R. Relative efficacy of selective COX-2 inhibitors compared with over-the-counter ibuprofen. Int J Clin Pract Suppl 135: 18\u201322, 2003."},{"key":"R7","doi-asserted-by":"publisher","DOI":"10.1016\/0952-3278(89)90019-7"},{"key":"R8","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.1998.275.6.F955"},{"key":"R9","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.physiol.70.113006.100614"},{"key":"R10","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2003.045914"},{"key":"R11","doi-asserted-by":"publisher","DOI":"10.1152\/ajpregu.00465.2002"},{"key":"R12","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(01)67397-X"},{"key":"R13","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1981.tb03123.x"},{"key":"R14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2005.01140.x"},{"key":"R15","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)00992-4"},{"key":"R16","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2006.11.070"},{"key":"R17","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(88)90221-X"},{"key":"R18","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(88)90722-4"},{"key":"R19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2006.01274.x"},{"key":"R20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704092"},{"key":"R21","doi-asserted-by":"publisher","DOI":"10.1152\/jn.2001.86.5.2276"},{"key":"R22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1995.tb15933.x"},{"key":"R23","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701903"},{"key":"R24","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.1999.276.1.H129"},{"key":"R25","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.1997.273.4.F538"},{"key":"R26","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(99)00833-X"},{"key":"R27","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2042.2005.01138.x"},{"key":"R28","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0611209104"},{"key":"R29","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000134186.58854.2c"},{"key":"R30","doi-asserted-by":"publisher","DOI":"10.1007\/BF00300786"},{"key":"R31","unstructured":"Sharif NA, Xu SX, Williams GW, Crider JY, Griffin BW, Davis TL. Pharmacology of [3H]prostaglandin E1\/[3H]prostaglandin E2 and [3H]prostaglandin F2alpha binding to EP3 and FP prostaglandin receptor binding sites in bovine corpus luteum: characterization and correlation with functional data. J Pharmacol Exp Ther 286: 1094\u20131102, 1998."},{"key":"R32","doi-asserted-by":"publisher","DOI":"10.1254\/jphs.FP0040098"},{"key":"R33","doi-asserted-by":"publisher","DOI":"10.1152\/ajprenal.00060.2005"},{"key":"R34","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.21-15-05670.2001"},{"key":"R35","doi-asserted-by":"publisher","DOI":"10.1186\/1744-8069-3-22"},{"key":"R36","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706715"}],"container-title":["American Journal of Physiology-Renal Physiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.physiology.org\/doi\/pdf\/10.1152\/ajprenal.00054.2008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,8]],"date-time":"2019-09-08T22:50:07Z","timestamp":1567983007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.physiology.org\/doi\/10.1152\/ajprenal.00054.2008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,8]]}},"alternative-id":["10.1152\/ajprenal.00054.2008"],"URL":"https:\/\/doi.org\/10.1152\/ajprenal.00054.2008","relation":{},"ISSN":["1931-857X","1522-1466"],"issn-type":[{"value":"1931-857X","type":"print"},{"value":"1522-1466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8]]}}}